Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.63 |
| ▸ | RXRB | P28702 | 1/20 | 0.63 |
| ▸ | RXRG | P48443 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 6/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 6/20 | 0.38 |
| ▸ | SMO | Q99835 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 3/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | PDE9A | O76083 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29433054 | 0.86 | RXRA (0.67) | RXRARXRBRXRGPOLBALDH1A1 | |
| SCHEMBL10231494 | 0.86 | RXRA (0.64) | RXRARXRBRXRGPOLBALDH1A1 | |
| SCHEMBL2471554 | 0.86 | RXRA (0.64) | RXRARXRBRXRGPOLBALDH1A1 | |
| SCHEMBL3640296 | 0.86 | RXRA (0.64) | RXRARXRBRXRGPOLBALDH1A1 | |
| SCHEMBL10231496 | 0.86 | RXRA (0.67) | RXRARXRBRXRGPOLBALDH1A1 | |
| SCHEMBL14553593 | 0.84 | RXRA (0.65) | RXRARXRBRXRGPOLBALDH1A1 | |
| SCHEMBL14553594 | 0.84 | RXRA (0.62) | RXRARXRBRXRGPOLBALDH1A1 | |
| SCHEMBL10231475 | 0.84 | RXRA (0.62) | RXRARXRBRXRGPOLBALDH1A1 | |
| SCHEMBL786142 | 0.83 | RXRA (0.61) | RXRARXRBRXRGPOLBALDH1A1 | |
| SCHEMBL28690927 | 0.83 | RXRA (0.64) | RXRARXRBRXRGPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299112-B2 | Estrogen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120071535-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071535-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | RXRA 34/4885RXRB 38/4885RXRG 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.